Allakos Inc

Allakos — Corporate Update (January 2025)

13 slides from Allakos's corporate update, Jan 27, 2025

  1. Slide 1: AK006 Phase 1 CSU Study Results & Business Update

    AK006 Phase 1 CSU Study Results & Business Update January 27, 2025 Exhibit 99.1

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the expectations of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”) regarding its financial position and gui

  3. Slide 3: Agenda

    Agenda Robert Alexander, CEO Introduction Chin Lee, CMO AK006 Phase 1 CSU Study Results Baird Radford, CFO Restructuring and Financial Implications Q&A

  4. Slide 4: Phase 1 Study of AK006 in Chronic Spontaneous Urticaria

    Phase 1 Study of AK006 in Chronic Spontaneous Urticaria

  5. Slide 5: AK006 Phase 1 Chronic Spontaneous Urticaria Study

    AK006 Phase 1 Chronic Spontaneous Urticaria Study Multi-center, randomized, double-blind, placebo-controlled study in CSU Diagnosis of CSU refractory to antihistamines Presence of itch and hives despite current use of antihistamines UAS7 score ≥16 and HSS7 score ≥8 at baseline Includes patients with

  6. Slide 6: Baseline Demographics & Patient Characteristics

    Baseline Demographics & Patient Characteristics Baseline Characteristics (mITT population) Phase 1 (CSU Cohort) Patient Characteristics AK006 n=23 Placebo n=11 All n=34 Age, mean ± SD 43 ± 14 45 ± 13 44 ± 13 Female sex, n (%) 19 (83%) 8 (73%) 27 (79%) White, n (%) 19 (83%) 7 (64%) 26 (76%) From US s

  7. Slide 7: CSU Cohort Efficacy Results

    CSU Cohort Efficacy Results UAS7 score is a Patient Reported Outcome questionnaire assessing itch severity and number of hives. Total range: 0 - 42 with higher scores denoting greater disease activity. Key Efficacy Endpoints (mITT population) AK006 n=23 Placebo n=11 UAS7 at Baseline, mean ± SD 34.4

  8. Slide 8: AK006 Was Well-Tolerated with a Favorable Safety Profile

    AK006 Was Well-Tolerated with a Favorable Safety Profile TEAEs occurring in at least two AK006-treated subjects, n (%) AK006 (n=23) Placebo (n=11) Headache 2 (8.7%) 1 (9.1%) Infusion related reaction 2 (8.7%) 0 COVID-19 2 (8.7%) 0

  9. Slide 9: Business Update

    Business Update

  10. Slide 10: Restructuring Activities and Planned Actions

    Restructuring Activities and Planned Actions The Company plans to discontinue AK006-related activities across clinical, manufacturing, research and administrative functions and reduce its workforce by approximately 75%. The Company plans to retain approximately 15 employees to explore strategic alte

  11. Slide 11: Cash Guidance

    Cash Guidance The Company ended the fourth quarter of 2024 with approximately $81 million in cash, cash equivalents, and investments (unaudited). The Company estimates that cash used in restructuring activities to closeout AK006 development, including severance and contractual payments to vendors wi

  12. Slide 12: Allakos”

    Allakos” S Ny 9 fe) =) a © 2 z

  13. Slide 13: Thank You

    Thank You

Allakos — Corporate Update (January 2025) on 6ix